Busulfan with 400 centigray of total body irradiation and higher dose fludarabine: An alternative regimen for hematopoietic stem cell transplantation in pediatric acute lymphoblastic leukemia
Pediatric Blood & Cancer · 2024
DOI: 10.1002/pbc.30844 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Jaspreet Gharial und 7 weiteren Autor:innen. Beteiligte Einrichtung: Section of Pediatric Hematology Oncology and Bone Marrow Transplantation, Alberta Children's Hospital, Calgary, Alberta, Canada. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Graft vs Host Disease, Leukemia, Myeloid, Acute. Die Arbeit nennt 41 Literaturangaben.
Abstract (Originalsprache)
Background
Hematopoietic stem cell transplantation can be curative for children with difficult‐to‐treat leukemia. The conditioning regimen utilized is known to influence outcomes. We report outcomes of the conditioning regimen used at the Alberta Children's Hospital, consisting of busulfan (with pharmacokinetic target of 3750 μmol*min/L/day ±10%) for 4 days, higher dose (250 mg/m 2 ) fludarabine and 400 centigray (cGy) of total body irradiation. Procedure This retrospective study involved children receiving transplant for acute lymphoblastic leukemia (ALL). It compared children who fell within the target range for busulfan with those who were either not measured or were measured and fell outside this range. All other treatment factors were identical.
Results
Twenty‐nine children (17 within target) were evaluated. All subjects engrafted neutrophils with a median [interquartile range] time of 14 days [8–30 days]. The cumulative incidence of acute graft‐versus‐host disease was 44.8% [95% confidence interval, CI: 35.6%–54.0%], while chronic graft‐versus‐host disease was noted in 16.0% [95% CI: 8.7%–23.3%]. At 2 years, the overall survival was 78.1% [95% CI: 70.8%–86.4%] and event‐free survival was 74.7% [95% CI: 66.4%–83.0%]. Cumulative incidence of relapse was 11.3% [95% CI: 5.1%–17.5%]. There were no statistically significant differences in between the group that received targeted busulfan compared with the untargeted group.
Conclusion
Our conditioning regiment for children with ALL resulted in outcomes comparable to standard treatment with acceptable toxicities and significant reduction in radiation dose. Targeting busulfan dose in this cohort did not result in improved outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Section of Pediatric Hematology Oncology and Bone Marrow Transplantation, Alberta Children's Hospital, Calgary, Alberta, Canada.
- Division of Pediatric Hematology/Oncology & Palliative Care, Stollery Children's Hospital, Edmonton, Alberta, Canada.
- Pharmacokinetic Scientist, Alberta Blood and Marrow Transplant Program, Foothills Hospital, and Tom Baker Cancer Centre, Calgary, Alberta, Canada.
ORCID-Profile: Jaspreet Gharial, Bill Kangarloo
Zitieren
APA
Gharial, J., Guilcher, G., Truong, T., Shah, R., Desai, S., Rojas-Vasquez, M., Kangarloo, B., & Lewis, V. (2024). Busulfan with 400 centigray of total body irradiation and higher dose fludarabine: An alternative regimen for hematopoietic stem cell transplantation in pediatric acute lymphoblastic leukemia. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30844
Vancouver
Gharial J, Guilcher G, Truong T, Shah R, Desai S, Rojas-Vasquez M, et al. Busulfan with 400 centigray of total body irradiation and higher dose fludarabine: An alternative regimen for hematopoietic stem cell transplantation in pediatric acute lymphoblastic leukemia. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.30844
BibTeX
@article{Gharial2024,
author = {Gharial, Jaspreet and Guilcher, Gregory and Truong, Tony and Shah, Ravi and Desai, Sunil and Rojas-Vasquez, Marta and Kangarloo, Bill and Lewis, Victor},
title = {Busulfan with 400 centigray of total body irradiation and higher dose fludarabine: An alternative regimen for hematopoietic stem cell transplantation in pediatric acute lymphoblastic leukemia},
journal = {Pediatric Blood & Cancer},
year = {2024},
doi = {10.1002/pbc.30844}
}
EUVIMED